Navigation Links
MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results
Date:8/14/2008

rketable securities, compared to $18.0 million at March 31, 2008 and $2.0 million as of year-end 2007.

FINANCIAL GUIDANCE

Total revenue guidance for 2008 is unchanged from prior forecasts and is expected to be approximately $10 million to $12 million, resulting from Keflex product sales and assuming no generic competition to Keflex 750 mg capsules occurs during the year. MiddleBrook intends to issue additional financial guidance for 2008 following the completion of its anticipated financing transaction with EGI.

ABOUT MIDDLEBROOK PHARMACEUTICALS:

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceutical company focused on the development and commercialization of anti-infective drug products that fulfill substantial unmet medical needs in the treatment of infectious disease. The Company is developing anti-infective drugs based on its novel biological finding that bacteria exposed to antibiotics in "pulses" are killed more efficiently and effectively than those under standard treatment regimens. Based on this finding, MiddleBrook has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS(R). The Company currently markets the Keflex(R) brand of cephalexin and has received regulatory approval for MOXATAG(TM) -- the first and only once-daily amoxicillin product approved for marketing in the U.S. For more on MiddleBrook, please visit http://www.middlebrookpharma.com.

About MOXATAG:

MOXATAG(TM) (amoxicillin extended-release) Tablets are a once-a-day extended-release formulation of amoxicillin for oral administration consisting of three components: one immediate-release and two delayed-release. The three components a
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results
2. MiddleBrook Pharmaceuticals Engages Morgan Stanley in Its Strategic Process
3. MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity
4. MiddleBrook Pharmaceuticals Reports Third Quarter 2007 Results
5. MiddleBrook Pharmaceuticals Raises Up to $10 Million from Deerfield Management
6. Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results
7. Lotus Pharmaceuticals Announces Conference Call to Discuss Second Quarter 2008 Results
8. MAP Pharmaceuticals Reports Second Quarter of 2008 Financial Results
9. Triax Pharmaceuticals Launches New Mid-Potency Corticosteroid Vehicle, Locoid Lotion 0.1%
10. ADVENTRX Pharmaceuticals Reports Second Quarter 2008 Financial Results and Business Update
11. Novis Pharmaceuticals Announces John W. Kilgour as Executive Vice-President of Sales & Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... The Coalition for,Pulmonary Fibrosis today announced 2007 National ... weekend in Washington, D.C., a,congressional reception that includes a ... with the National Institutes of Health. More,than 40 Idiopathic ... the Hill next week to meet with Members of ...
... As we age, our brains slowly shrink in volume ... lobes, the seat of executive functioning. Executive functions include ... aging population, an inability to inhibit unwanted thoughts and ... awry. , In a study appearing in the ...
... rather than womens newfound economic independence can explain why ... and why the trend may only be temporary, says ... women acquired significant control over their own fertility, and ... burden of raising children, says Lonnie Aarssen, a Biology ...
... 21 September 2007: New guidelines on the diagnosis and ... the Archives of Disease in Childhood, are set to ... the most common food allergy in children.1 The Guidelines ... Allergy recommend only extensively hydrolysed (eHF) and amino acid-based ...
... may take decades to reverse the health threats, experts say ... and ,90s, Americans tried to control their weight by watching ... paid little mind to total calories and physical activity. And ... , "It was just an end run around the issue ...
... RESTON, Va. -- Attention scientific researchers: SNM invites ... especially those involving non-radioactive molecular imaging techniques and ... June 1418, 2008, in New Orleans, La. SNM, ... nuclear medicine professionals, will showcase these studies in ...
Cached Medicine News:Health News:CPF Announces National IPF Awareness Week Activities 2Health News:CPF Announces National IPF Awareness Week Activities 3Health News:Brain atrophy in elderly leads to unintended racism, depression and problem gambling 2Health News:Is there really a 'mommy' gene in women? 2Health News:New guidelines set to improve standard of cows' milk allergy care 2Health News:New guidelines set to improve standard of cows' milk allergy care 3Health News:Childhood Obesity Epidemic a Long-Term Challenge 2Health News:Childhood Obesity Epidemic a Long-Term Challenge 3Health News:SNM seeks novel approaches to molecular imaging to showcase at annual meeting 2
(Date:1/14/2014)... 14, 2014  Luminex Corporation (Nasdaq: LMNX ... for the fourth quarter of 2013 on Monday, February ... scheduled for release after the close of trading. ... will hold a conference call to discuss the operating ... twelve months ended December 31, 2013 on February 3, ...
(Date:1/14/2014)... Ore. , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s ... a targeting guide with accompanying instrumentation to place and ... adjunct to the soft tissue (e.g. ligament) repair or ... tissue repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ... maintain the anatomical reduction (spacing) of the scaphoid and ...
(Date:1/14/2014)... N.Y. , Jan. 14, 2014   Oligomerix, ... development of disease modifying therapeutics for Alzheimer,s disease ... relocation of its corporate headquarters to ... 2014 and expanded lease agreement for additional laboratory ... Oligomerix, which is focused on the development of ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... HealthCare Pharmaceuticals is pleased to announce it will support the New Jersey ... is the second year in a row that Bayer HealthCare Pharmaceuticals has sponsored the ... , , ... , , ...
... Calif. , July 22 SRI International and the ... Collaborative (the Multidisciplinary Initiative for Surgical Technology Research Advanced Laboratory), in ... $1M grant by the Food and Drug Administration (FDA) ... care. , , ...
Cached Medicine Technology:Bayer HealthCare Pharmaceuticals Supports New Jersey Governor's School in the Sciences at Drew University 2Bayer HealthCare Pharmaceuticals Supports New Jersey Governor's School in the Sciences at Drew University 3SRI International and Stanford University School of Medicine's MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices 2SRI International and Stanford University School of Medicine's MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices 3SRI International and Stanford University School of Medicine's MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices 4SRI International and Stanford University School of Medicine's MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices 5SRI International and Stanford University School of Medicine's MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices 6SRI International and Stanford University School of Medicine's MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices 7
Latex agglutination slide test for the qualitative and semi-quantitative in vitro determination of Rheumatoid Factor in serum....
For the quantitative in vitro determination of IgE in Human Serum or Plasma....
For the quantitative in vitro determination of IgG in serum and plasma. This product is suitable for use on the Aeroset...
Latex-enhanced immunoturbidimetric assay for the quantitative in vitro determination of C-reactive protein in serum and plasma...
Medicine Products: